Skip to main content
Top
Published in: Pituitary 4/2010

01-12-2010

The clinical significance of MIB-1 labeling index in pituitary adenomas

Authors: Geeta Chacko, Ari G. Chacko, Kalman Kovacs, Bernd W. Scheithauer, Sunithi Mani, J. P. Muliyil, M. S. Seshadri

Published in: Pituitary | Issue 4/2010

Login to get access

Abstract

Pituitary adenomas are unique in several ways—they are rarely malignant and yet can be invasive of several compartments. Recurrences in tumors with bland histological features that have been radically excised are a reason for frustration faced by endocrinologists and neurosurgeons in treatment of pituitary adenomas. Several attempts have therefore been made to determine the growth potential of pituitary adenomas. The aim of the present study was to define the biological significance of the MIB-1 labelling index (MIB-1 LI) in pituitary adenomas. The study included 159 cases of surgically treated pituitary adenoma seen in a single institution. MIB-1 LI was not found to be related to age or gender. The mean MIB-1 LI for clinically functional adenomas was marginally higher than that for clinically non-functional adenomas. There was a significant difference in the MIB-1 LI for tumors with a maximum diameter of more than 4 cm at a MIB-1 LI of ≥2%, however this difference was not statistically significant at a higher MIB-1 LI cut off value of >3%. The mean MIB-1 LI was significantly higher in tumors causing hydrocephalus and in those with cavernous sinus invasion and not when invasion was defined as invasion by tumor in any direction. We conclude that large pituitary macroadenomas, tumors filling the third ventricle causing hydrocephalus and tumors with true cavernous sinus invasions are more likely to have a higher proliferation index. Close follow up of tumors showing these imaging features would be recommended.
Literature
1.
go back to reference DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) Pathology and genetics. Tumors of endocrine organs In: World Health Organization Classification of Tumors Lyon: IARC Press DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) Pathology and genetics. Tumors of endocrine organs In: World Health Organization Classification of Tumors Lyon: IARC Press
4.
go back to reference Farrell WE (2006) Pituitary tumours: findings from whole genome analyses. Endocr Relat Cancer 13:707–716CrossRefPubMed Farrell WE (2006) Pituitary tumours: findings from whole genome analyses. Endocr Relat Cancer 13:707–716CrossRefPubMed
5.
go back to reference Pack SD, Qin LX, Pak E et al (2005) Common genetic changes in hereditary and sporadic pituitary adenomas detected by comparative genomic hybridization. Genes Chromosomes Cancer 43:72–82CrossRefPubMed Pack SD, Qin LX, Pak E et al (2005) Common genetic changes in hereditary and sporadic pituitary adenomas detected by comparative genomic hybridization. Genes Chromosomes Cancer 43:72–82CrossRefPubMed
6.
go back to reference Szymas J, Schluens K, Liebert W, Petersen I (2002) Genomic instability in pituitary adenomas. Pituitary 5:211–219CrossRefPubMed Szymas J, Schluens K, Liebert W, Petersen I (2002) Genomic instability in pituitary adenomas. Pituitary 5:211–219CrossRefPubMed
7.
go back to reference Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S (1999) Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5:1317–1321CrossRefPubMed Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S (1999) Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5:1317–1321CrossRefPubMed
8.
go back to reference McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ (2002) Vascular endothelial growth factor, its receptor kdr/flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238–4244CrossRefPubMed McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ (2002) Vascular endothelial growth factor, its receptor kdr/flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238–4244CrossRefPubMed
9.
go back to reference De Martino I, Visone R, Wierinckx A, Palmieri D, Ferraro A, Cappabianca P, Chiappetta G, Forzati F, Lombardi G, Colao A, Trouillas J, Fedele M, Fusco A (2009) HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res 69:1844–1850CrossRefPubMed De Martino I, Visone R, Wierinckx A, Palmieri D, Ferraro A, Cappabianca P, Chiappetta G, Forzati F, Lombardi G, Colao A, Trouillas J, Fedele M, Fusco A (2009) HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res 69:1844–1850CrossRefPubMed
10.
go back to reference Vlotides G, Eigler T, Melmed S (2007) Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 28:165–186CrossRefPubMed Vlotides G, Eigler T, Melmed S (2007) Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 28:165–186CrossRefPubMed
11.
go back to reference Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B, Klibanski A (2002) Loss of expression of gadd45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab 87:1262–1267CrossRefPubMed Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B, Klibanski A (2002) Loss of expression of gadd45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab 87:1262–1267CrossRefPubMed
13.
go back to reference Chatterjee S, May PL, Forster G, Spiller D, Jeffreys RV (1993) Prediction of recurrence in pituitary tumours: a flow cytometric study using in vivo bromodeoxyuridine. Br J Neurosurg 7:165–169CrossRefPubMed Chatterjee S, May PL, Forster G, Spiller D, Jeffreys RV (1993) Prediction of recurrence in pituitary tumours: a flow cytometric study using in vivo bromodeoxyuridine. Br J Neurosurg 7:165–169CrossRefPubMed
14.
go back to reference Fitzgibbons PL, Appley AJ, Turner RR, Bishop PC, Parker JW, Breeze RE, Weiss MH, Apuzzo ML (1988) Flow cytometric analysis of pituitary tumors correlation of nuclear antigen p105 and DNA content with clinical behavior. Cancer 62:1556–1560CrossRefPubMed Fitzgibbons PL, Appley AJ, Turner RR, Bishop PC, Parker JW, Breeze RE, Weiss MH, Apuzzo ML (1988) Flow cytometric analysis of pituitary tumors correlation of nuclear antigen p105 and DNA content with clinical behavior. Cancer 62:1556–1560CrossRefPubMed
15.
go back to reference Gandour-Edwards R, Kapadia SB, Janecka IP, Martinez AJ, Barnes L (1995) Biologic markers of invasive pituitary adenomas involving the sphenoid sinus. Mod Pathol 8:160–164PubMed Gandour-Edwards R, Kapadia SB, Janecka IP, Martinez AJ, Barnes L (1995) Biologic markers of invasive pituitary adenomas involving the sphenoid sinus. Mod Pathol 8:160–164PubMed
16.
go back to reference Hsu DW, Hakim F, Biller BM, de la Monte S, Zervas NT, Klibanski A, Hedley-Whyte ET (1993) Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 78:753–761CrossRefPubMed Hsu DW, Hakim F, Biller BM, de la Monte S, Zervas NT, Klibanski A, Hedley-Whyte ET (1993) Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 78:753–761CrossRefPubMed
17.
go back to reference Kitz K, Knosp E, Koos WT, Korn A (1991) Proliferation in pituitary adenomas: measurement by MAb KI 67. Acta Neurochir Suppl (Wien) 53:60–64 Kitz K, Knosp E, Koos WT, Korn A (1991) Proliferation in pituitary adenomas: measurement by MAb KI 67. Acta Neurochir Suppl (Wien) 53:60–64
18.
go back to reference Knosp E, Kitz K, Perneczky A (1989) Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 25:927–930CrossRefPubMed Knosp E, Kitz K, Perneczky A (1989) Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 25:927–930CrossRefPubMed
19.
go back to reference Landolt AM, Shibata T, Kleihues P (1987) Growth rate of human pituitary adenomas. J Neurosurg 67:803–806CrossRefPubMed Landolt AM, Shibata T, Kleihues P (1987) Growth rate of human pituitary adenomas. J Neurosurg 67:803–806CrossRefPubMed
20.
go back to reference Lath R, Chacko G, Chandy MJ (2001) Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody. Neurol India 49:144–147PubMed Lath R, Chacko G, Chandy MJ (2001) Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody. Neurol India 49:144–147PubMed
21.
go back to reference Mastronardi L, Guiducci A, Puzzilli F (2001) Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 1:12CrossRefPubMed Mastronardi L, Guiducci A, Puzzilli F (2001) Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 1:12CrossRefPubMed
22.
go back to reference Schreiber S, Saeger W, Ludecke DK (1999) Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary 1:213–220CrossRefPubMed Schreiber S, Saeger W, Ludecke DK (1999) Proliferation markers in different types of clinically non-secreting pituitary adenomas. Pituitary 1:213–220CrossRefPubMed
23.
go back to reference Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99–106CrossRefPubMed Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99–106CrossRefPubMed
24.
go back to reference Paek KI, Kim SH, Song SH, Choi SW, Koh HS, Youm JY, Kim Y (2005) Clinical significance of Ki-67 labeling index in pituitary macroadenoma. J Korean Med Sci 20:489–494CrossRefPubMed Paek KI, Kim SH, Song SH, Choi SW, Koh HS, Youm JY, Kim Y (2005) Clinical significance of Ki-67 labeling index in pituitary macroadenoma. J Korean Med Sci 20:489–494CrossRefPubMed
25.
go back to reference Pizarro CB, Oliveira MC, Coutinho LB, Ferreira NP (2004) Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res 37:235–243CrossRefPubMed Pizarro CB, Oliveira MC, Coutinho LB, Ferreira NP (2004) Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res 37:235–243CrossRefPubMed
26.
go back to reference Cottier JP, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M, Herbreteau D (2000) Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215:463–469PubMed Cottier JP, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M, Herbreteau D (2000) Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215:463–469PubMed
27.
go back to reference Devaprasath A, Chacko G (2003) Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas. Neurol India 51:336–340PubMed Devaprasath A, Chacko G (2003) Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas. Neurol India 51:336–340PubMed
28.
go back to reference Yonezawa K, Tamaki N, Kokunai T (1997) Clinical features and growth fractions of pituitary adenomas. Surg Neurol 48:494–500CrossRefPubMed Yonezawa K, Tamaki N, Kokunai T (1997) Clinical features and growth fractions of pituitary adenomas. Surg Neurol 48:494–500CrossRefPubMed
29.
go back to reference Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S (2003) Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time patient age and MIB-1 index. J Neurosurg 98:359–365CrossRefPubMed Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S (2003) Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time patient age and MIB-1 index. J Neurosurg 98:359–365CrossRefPubMed
31.
go back to reference Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P, Giovanelli M (2000) Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 47:1313–1318CrossRefPubMed Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P, Giovanelli M (2000) Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 47:1313–1318CrossRefPubMed
32.
go back to reference Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102–2107CrossRefPubMed Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102–2107CrossRefPubMed
33.
go back to reference Calle-Rodrigue RD, Giannini C, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT, Stefaneanu L, Ebright AB, Abboud CF, Davis DH (1998) Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 73:1046–1052CrossRefPubMed Calle-Rodrigue RD, Giannini C, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT, Stefaneanu L, Ebright AB, Abboud CF, Davis DH (1998) Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 73:1046–1052CrossRefPubMed
34.
go back to reference Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki T, Riehle DL, Laws ER Jr (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59:341–353CrossRefPubMed Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki T, Riehle DL, Laws ER Jr (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59:341–353CrossRefPubMed
35.
go back to reference Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Ruggeri A, Peciarolo A (2000) Adrenocorticotropic hormone secreting pituitary adenomas: analysis of growth fraction using the MIB-1 antibody. Tumori 86:229–232PubMed Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Ruggeri A, Peciarolo A (2000) Adrenocorticotropic hormone secreting pituitary adenomas: analysis of growth fraction using the MIB-1 antibody. Tumori 86:229–232PubMed
36.
go back to reference Eda M, Saeki N, Fujimoto N, Sunami K (2002) Demonstration of the optic pathway in large pituitary adenoma on heavily t2 weighted mr images. Br J Neurosurg 16:21–29CrossRefPubMed Eda M, Saeki N, Fujimoto N, Sunami K (2002) Demonstration of the optic pathway in large pituitary adenoma on heavily t2 weighted mr images. Br J Neurosurg 16:21–29CrossRefPubMed
37.
go back to reference Iuchi T, Saeki N, Osato K, Yamaura A (2000) Proliferation vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir (Wien) 142:1345–1351CrossRef Iuchi T, Saeki N, Osato K, Yamaura A (2000) Proliferation vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir (Wien) 142:1345–1351CrossRef
38.
go back to reference Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38:765–770CrossRefPubMed Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38:765–770CrossRefPubMed
39.
go back to reference Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99:674–679CrossRefPubMed Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99:674–679CrossRefPubMed
40.
go back to reference Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T (1995) Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas. Acta Neurochir (Wien) 136:37–43CrossRef Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T (1995) Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas. Acta Neurochir (Wien) 136:37–43CrossRef
41.
go back to reference Bannur U, Chacko G, Chandy MJ (1998) AgNOR count as an index of invasion in pituitary adenoma. Br J Neurosurg 12:582–584CrossRef Bannur U, Chacko G, Chandy MJ (1998) AgNOR count as an index of invasion in pituitary adenoma. Br J Neurosurg 12:582–584CrossRef
42.
go back to reference Goel A, Nadkarni T, Muzumdar D, Desai K, Phalke U, Sharma P (2004) Giant pituitary tumors: a study based on surgical treatment of 118 cases. Surg Neurol 61:436–445CrossRefPubMed Goel A, Nadkarni T, Muzumdar D, Desai K, Phalke U, Sharma P (2004) Giant pituitary tumors: a study based on surgical treatment of 118 cases. Surg Neurol 61:436–445CrossRefPubMed
43.
go back to reference Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T (1996) The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir (Wien) 138:1449–1455CrossRef Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T (1996) The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir (Wien) 138:1449–1455CrossRef
45.
go back to reference de Aguiar PH, Aires R, Laws ER, Isolan GR, Logullo A, Patil C, Katznelson L (2010) Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review. Neurol Res (EPub ahead of print) de Aguiar PH, Aires R, Laws ER, Isolan GR, Logullo A, Patil C, Katznelson L (2010) Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review. Neurol Res (EPub ahead of print)
46.
go back to reference Widhalm G, Wolfsberger S, Preusser M, Fischer I, Woehrer A, Wunderer J, Hainfellner JA, Knosp E (2009) Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J Neurosurg 111:563–571CrossRefPubMed Widhalm G, Wolfsberger S, Preusser M, Fischer I, Woehrer A, Wunderer J, Hainfellner JA, Knosp E (2009) Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J Neurosurg 111:563–571CrossRefPubMed
47.
go back to reference Salehi F, Agur A, Scheithauer BW et al (2009) Ki-67 in pituitary neoplasms: a review—part I. Neurosurgery 65:429–437 discussion 437CrossRefPubMed Salehi F, Agur A, Scheithauer BW et al (2009) Ki-67 in pituitary neoplasms: a review—part I. Neurosurgery 65:429–437 discussion 437CrossRefPubMed
Metadata
Title
The clinical significance of MIB-1 labeling index in pituitary adenomas
Authors
Geeta Chacko
Ari G. Chacko
Kalman Kovacs
Bernd W. Scheithauer
Sunithi Mani
J. P. Muliyil
M. S. Seshadri
Publication date
01-12-2010
Publisher
Springer US
Published in
Pituitary / Issue 4/2010
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-010-0242-7

Other articles of this Issue 4/2010

Pituitary 4/2010 Go to the issue